IBD's list of the 50 Most Sustainable Companies for 2025 combines high sustainability scores and superior stock ratings. Would these be a good fit for your portfolio?

Hims stock surged Wednesday, topping a buy point, after the telehealth behemoth announced a menopause care program.

US clinical-stage biotech Spyre Therapeutics on Wednesday announced the closing of its previously announced underwritten public offering of 17,094,594 shares of its common stock, including the full ...

The rate of Americans diagnosed with digestive disorders and gastrointestinal cancers is rising, especially in those ages 50 ...

When Phyllis Burk was diagnosed with Crohn’s disease nearly 50 years ago, it wasn’t as simple as looking up information ...

Diwali's festive glow masks a growing concern: colorectal cancer is increasingly striking young adults, a trend alarming ...

Jefferies LLC, TD Securities (USA) LLC, Leerink Partners LLC and Stifel, Nicolaus & Company, Incorporated acted as the joint book-running managers for the offering. Wedbush Securities Inc. acted as ...

The FDA has approved an updated indication for upadacitinib (Rinvoq; AbbVie) in inflammatory bowel disease (IBD), allowing its use in adults with moderately to severely active ulcerative colitis or ...

Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic ...

As the U.S. IPO market opens back up, here's how biotech CEO Marc de Garidel says business leaders can capitalize.

Drug candidates spanning oncology, neurology, rare diseases and more are approaching critical development as the calendar turns to 2026.